Data from a phase 3 clinical trial for REGEN-COV, a combination monoclonal antibody therapy (casirivimab with imdevimab), is part of the NIH-sponsored COVID Prevention Network, co-led by Myron Cohen, MD, the Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology.
Regeneron Pharmaceuticals, Inc. announced positive data from a phase 3 trial of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via injection. REGEN-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% and by 76% after the third day. The trial also demonstrated that REGEN-COV shortened symptom duration, markedly reduced viral levels, and reduced the risk of spreading the infection within individual households.
Read more from the UNC Health and UNC School of Medicine Newsroom.